Equities

SS Innovations International Inc

SSII:PKC

SS Innovations International Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.50
  • Today's Change0.00 / 0.00%
  • Shares traded3.75k
  • 1 Year change-56.79%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 19:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company is developing a fully autonomous medical robotic system using software, which integrates artificial intelligence (AI) and deep learning, or machine learning (DL). Its product range includes its SSI Mantra surgical robotic system, and SSI Mudra is its range of surgical instruments capable of supporting a variety of surgical procedures, including robotic cardiac surgery. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset. The SSi Mantra is comprised of vision cart, which provides an additional 32-inch 3D 4K resolution monitor, identical to the surgeon’s console, for the operating room staff.

  • Revenue in USD (TTM)5.88m
  • Net income in USD-20.94m
  • Incorporated2015
  • Employees239.00
  • Location
    SS Innovations International Inc1600 Se 15Th Street, #512ORLANDO 33316United StatesUSA
  • Phone+1 (954) 478-1410
  • Fax+1 (407) 849-2719
  • Websitehttps://www.ssinnovations.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Harrow Inc138.68m-31.33m571.77m315.00--9.44--4.12-0.9079-0.90794.091.710.54064.216.75440,244.40-12.21-10.86-13.79-12.7169.7770.75-22.59-15.352.75-0.33020.7536--46.9525.77-73.30--143.88--
Third Harmonic Bio Inc0.00-30.82m579.37m30.00--2.12-----0.9461-0.94610.006.710.00----0.00-10.70---10.91--------------0.00------12.32------
Northwest Biotherapeutics Inc1.93m-64.37m579.93m25.00------300.17-0.0573-0.05730.0017-0.040.0653----77,280.00-211.53-381.58---------3,240.11-6,479.25--------14.8036.2138.71--77.88--
Avid Bioservices Inc136.74m-17.96m584.01m365.00--3.24--4.27-0.284-0.2842.172.840.3023.184.89374,616.40-3.9710.73-6.0315.227.4722.72-13.1325.920.3097-5.040.45480.0024.8122.72-99.56--82.90--
Taysha Gene Therapies Inc14.16m-118.01m587.24m52.00--10.91--41.48-1.19-1.190.08960.28790.1112----272,230.80-92.70---146.13-------833.60------0.4315--517.55--32.80------
PetIQ Inc1.12bn7.34m589.38m1.93k91.872.4910.860.52630.21560.215636.407.951.294.585.67579,376.600.8933-4.321.14-5.2323.6620.050.6951-3.661.251.840.6517--19.5815.83104.42--4.96--
Cabaletta Bio Inc0.00-76.87m590.68m118.00--2.75-----1.73-1.730.004.600.00----0.00-44.70-33.76-48.55-35.68------------0.00-------27.75------
SS Innovations International Inc5.88m-20.94m597.54m239.00--41.79--101.63-0.1293-0.12930.040.08380.3939--2.5324,601.30-140.31-161.38-253.40-449.7612.13-79.79-356.17-495.771.30-52.510.2963-------846.31--159.31--
ORIC Pharmaceuticals Inc0.00-101.76m608.15m102.00--1.85-----1.81-1.810.004.870.00----0.00-35.25-33.92-37.18-35.77------------0.00-------12.99--10.09--
Mind Medicine (MindMed) Inc0.00-125.32m621.70m57.00--3.14-----2.94-2.940.002.760.00----0.00-58.14---73.35--------------0.0675-------68.55------
Phathom Pharmaceuticals Inc2.59m-246.63m625.74m452.00------241.23-4.41-4.410.047-2.540.0104----5,738.94-98.55-83.26-111.44-93.7777.14---9,507.71-135,982.007.80-5.291.46-------1.96------
enGene Holdings Inc0.00-106.80m625.79m33.00--5.28-----4.60-4.600.002.69------0.00-------------------1.370.2653-------260.87------
Allogene Therapeutics Inc87.00k-292.30m627.24m232.00--1.11--7,209.61-1.78-1.780.00052.710.0001----375.00-43.85-28.46-47.04-30.21-----335,973.60-1,123.44----0.00---39.10--3.86---14.06--
GeneDx Holdings Corp221.85m-135.02m628.14m1.00k--3.03--2.83-5.25-5.258.607.930.47219.167.27221,849.00-28.73---35.07--50.5711.50-60.86-121.102.99-130.270.2015---13.698.7267.98--7.77--
Altimmune Inc410.00k-92.77m630.97m59.00--3.65--1,538.95-1.59-1.590.0072.440.0022--1.476,949.15-49.42-39.62-53.14-42.58-----22,626.10-1,811.89----0.00--726.47-47.15-4.41---45.92--
Aerovate Therapeutics Inc0.00-82.19m631.19m51.00--6.72-----3.03-3.030.003.260.00----0.00-71.09---80.16--------------0.00-------46.61------
Data as of May 17 2024. Currency figures normalised to SS Innovations International Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.